{"prompt": "['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Study Protocol', 'gsk', 'Sponsor:', 'GlaxoSmithKline Biologicals', \"Rue de l'institut 89,\", '1330 Rixensart, Belgium', 'eTrack study number and', '201112 (EPI-NTHI-001 BOD APA)', 'Abbreviated Title', 'Date of protocol', 'Final Version 1: 02 March 2014', 'Date of protocol', 'Amendment 1 Final: 13 February 2017', 'amendment', 'Amendment 2 Final: 20 October 2017', 'Amendment 3 Final: 19 October 2018', 'Title', 'Occurrence of potential bacterial and viral pathogens', 'in stable chronic obstructive pulmonary disease', '(COPD) and during acute exacerbations of COPD', '(AECOPD), in Asia Pacific.', 'Detailed Title', 'A prospective, epidemiological, multi-country, cohort', 'study to assess the occurrence of potential bacterial', 'and viral pathogens in stable chronic obstructive', 'pulmonary disease (COPD) and during acute', 'exacerbations of COPD (AECOPD), in moderate to', 'very severe COPD patients, in Asia Pacific.', 'PPD', 'Co-ordinating author', 'Scientific Writer', ',', 'Contributing authors', 'PPD', ', Epidemiologist', 'PPD', 'Clinical Research and', 'Development Lead', 'PPD', 'Clinical Research', ',', 'and Development Lead', 'PPD', 'Senior Epidemiology Expert', 'PPD', 'Vaccine Development Leader', 'PPD', 'Biostatistician', 'PPD', 'Lead', 'statistician', 'PPD', 'Project', 'Delivery Lead', 'PPD', 'Study Delivery Lead', 'PPD', 'Study Delivery Manager,', '(External Consultant [Freelance]for GSK', 'Biologicals)', 'PPD', 'Senior', 'Manager, Oversight Data Management', '19-OCT-2018', '1', '75661ebdab2e949f7a1f1bc2071b9dec72acecct']['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'eTrack study number and', '201112 (EPI-NTHI-001 BOD APA)', 'Abbreviated Title', 'Detailed Title', 'A prospective, epidemiological, multi-country, cohort', 'study to assess the occurrence of potential bacterial', 'and viral pathogens in stable chronic obstructive', 'pulmonary disease (COPD) and during acute', 'exacerbations of COPD (AECOPD), in moderate to', 'very severe COPD patients, in Asia Pacific.', 'Contributing authors', 'PPD', 'Study Data Manager', 'PPD', 'Vaccine Supply', 'Coordinator (CVO Europe, for GSK Biologicals)', 'PPD', 'Clinical Readout Team', 'Leader, Clinical Laboratory Sciences', 'PPD', 'Study Manager, GVCL', '(Business & Decision Life sciences, for GSK', 'Biologicals), PPD', 'Study Manager,', 'Clinical Laboratory Sciences', 'PPD', 'Global', 'Regulatory Lead and', 'PPD', 'Global', 'Regulatory Affairs representative', 'PPD', 'and', 'PPD', 'PPD', 'and', 'PPD', 'PPD', 'and', 'PPD', 'Clinical Safety Representatives', 'PPD', 'Expert Scientist, Clinical', 'Laboratory Sciences', 'PPD', 'Study Data Manager (Business &', 'Decision Life Sciences, for GSK Biologicals)', 'Dr. PPD', ', University of Sydney Head,', 'Respiratory Trials, Contributing author from The', 'George Institute for Global Health, Australia', \"GSK Biologicals' Protocol DS v15.0\", 'C 2014-2018 GSK group of companies or its licensor.', '19-OCT-2018', '2', '75661ebdab2e949f7a1f1bc2071b9dec72acecct']['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Protocol Amendment 3 Sponsor Signatory Approval', 'eTrack study number and', '201112 (EPI-NTHI-001 BOD APA)', 'Abbreviated Title', 'Date of protocol amendment', 'Amendment 3 Final: 19 October 2018', 'Detailed Title', 'A prospective, epidemiological, multi-country, cohort', 'study to assess the occurrence of potential bacterial', 'and viral pathogens in stable chronic obstructive', 'pulmonary disease (COPD) and during acute', 'exacerbations of COPD (AECOPD), in moderate to', 'very severe COPD patients, in Asia Pacific.', 'Sponsor signatory', 'Ashwani Kumar Arora', 'Clinical and Epidemiology Project Lead', 'Signature', 'Date', 'For internal use only', 'Checksum', '!Ver.!Created On -', '-', '15661ebdab2e949f7alflbc2071b9dec72aceccf2.0 10/25/2018 6:16:52 PM - -', '19-OCT-2018', '3', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']\n\n###\n\n", "completion": "END"}